FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

OMB APPROVAL							
OMB Number: 3235-028							
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
mondon r(b).

					01	Sect	ion 30(h)	of the	Ínvestmen	t Con	npany Act	of 19	940						
1. Name and Address of Reporting Person* Biller Jonathan				2. Issuer Name and Ticker or Trading Symbol AGIOS PHARMACEUTICALS, INC. [AGIO]									(Che	eck all applic Directo	onship of Reporting Pers ill applicable) Director Officer (give title below)		son(s) to Issuer 10% Owner Other (specify below)		
(Last) (First) (Middle) C/O AGIOS PHARMACEUTICALS, INC. 88 SIDNEY STREET				3. Date of Earliest Transaction (Month/Day/Year) 02/10/2021									Chief Financial Officer						
(Street)	IDGE M	1A	02139		4. If Amendment, Date of Original Filed (Month/Day/Year)							Line	ndividual or Joint/Group Filing (Check Applicable X Form filed by One Reporting Person Form filed by More than One Reporting Person				n		
(City)	(5	State)	(Zip)																
1. Title of Security (Instr. 3) 2. Transa Date						Code (Instr. 5)			(A) or	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)		Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)					
			Table II -							ispo	sed of,			icially	Owned	and 4)	<u> </u>		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemee Execution I if any (Month/Day	Date, Ti	4. Transaction Code (Instr. 8)		saction of		6. Date Exercisable and Expiration Date (Month/Day/Year)				7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	curity derivative		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)

Date Exercisable

(2)

(3)

Expiration Date

(2)

02/10/2031

Title

Commo

Common

stock

Explanation of Responses:

(1)

\$56.68

- 1. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- 2. The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments.
- 3. This option was granted on February 10, 2021. The shares underlying this option vest as to 25% of the underlying shares on February 10, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter.

(D)

(A)

11,000

44,000

Remarks:

Restricted

stock units Stock option (right to

buy)

/s/ William Cook, as Attorney in Fact for Jonathan Biller

or Number

of Shares

11,000

44,000

\$<mark>0</mark>

\$0

02/12/2021

11,000

44,000

D

D

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

02/10/2021

02/10/2021

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code

A

A

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.